Park Avenue Securities LLC Increases Holdings in TransMedics Group, Inc. $TMDX

Park Avenue Securities LLC lifted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 127.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,559 shares of the company’s stock after purchasing an additional 4,237 shares during the quarter. Park Avenue Securities LLC’s holdings in TransMedics Group were worth $848,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Opal Wealth Advisors LLC purchased a new position in TransMedics Group during the 2nd quarter valued at about $26,000. Salomon & Ludwin LLC bought a new position in shares of TransMedics Group in the third quarter valued at approximately $28,000. Sound Income Strategies LLC bought a new position in shares of TransMedics Group in the second quarter valued at approximately $48,000. Elevation Point Wealth Partners LLC purchased a new position in TransMedics Group during the second quarter valued at approximately $48,000. Finally, Farther Finance Advisors LLC increased its holdings in TransMedics Group by 100.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 562 shares of the company’s stock worth $63,000 after acquiring an additional 281 shares during the period. Institutional investors own 99.67% of the company’s stock.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director David Weill sold 5,000 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the sale, the director directly owned 12,134 shares of the company’s stock, valued at $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Edward M. Basile sold 4,142 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total transaction of $540,323.90. Following the sale, the director owned 2,866 shares of the company’s stock, valued at approximately $373,869.70. The trade was a 59.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 13,062 shares of company stock valued at $1,797,634. Insiders own 7.00% of the company’s stock.

TransMedics Group Trading Down 0.5%

Shares of TMDX stock opened at $141.96 on Thursday. The business has a 50-day moving average price of $130.01 and a two-hundred day moving average price of $122.42. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $156.00. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The firm has a market cap of $4.85 billion, a P/E ratio of 57.47 and a beta of 2.03.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. The company had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.TransMedics Group’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period last year, the firm posted $0.12 EPS. Equities analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on TMDX. Wall Street Zen raised shares of TransMedics Group from a “hold” rating to a “buy” rating in a report on Sunday, December 28th. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Jefferies Financial Group started coverage on TransMedics Group in a research report on Monday, October 13th. They set a “buy” rating and a $145.00 target price for the company. Zacks Research lowered TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Finally, Piper Sandler reiterated an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus target price of $144.25.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.